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Background
Human Mesenchymal Stromal Cells (MSC) are multipo-
tent cells residing in all support and structural tissues of
the organism and they are capable of extensive expan-
sion in vitro while preserving their identity, potency and
genetic stability [1]. Umbilical cord (UC)-derived MSC
(UC-MSC) are thought to be more primitive progenitor
cells than those isolated from bone marrow or lipoaspi-
rates [2]. The fact that the umbilical cord is a waste tis-
sue is an added value to the isolation of UC-MSC from
this source for the generation of cell banks for later use
in the allogeneic treatment context as off-the-shelf pro-
duct [3]. However, several limitations exist regarding the
success of the isolation and expansion of UC-MSC up
to clinically relevant doses under Good Manufacturing
Practice (GMP) environments, provided that current
methods 1) require large quantities of tissue processed
immediately after birth, 2) are time-consuming, and 3)
result in low cellular yields.
In the present study, two methods for UC-MSC deri-
vation from the Wharton’s Jelly (WJ) of the UC tissue
were tested, namely 1) mechanical scrapping of WJ, and
2) enzymatic digestion of umbilical cord tissue for
further use in GMP-compliant cell culture production
bioprocesses.
Materials and methods
UC tissue fragments collected in the Concordia Program
(http://www.bancsang.net/professionals/en_concordia/)
with appropriate donor informed consent were used for
sourcing UC-MSC. UC samples were washed twice with
sterile Phosphate Buffer Solution (PBS, Gibco) for
removing any traces of blood, transferred to a Petri dish
and cut into two fragments for testing either one of the
two protocols for UC-MSC derivation: mechanical or
enzymatic, respectively. In both cases, the fragments
were weighted, cut longitudinally and split open to
expose the inner surface for then removing the two
arteries and the vein (Figure 1, top panel). For the
mechanical method, a surgical scalpel was used for
scraping the Wharton’s Jelly, which was then spread
uniformly onto the plastic surface of a 100 mm cell cul-
ture plate (Corning) and incubated 30 min at 37ºC
(Figure 1, middle panel). In the enzymatic digestion, the
tissue was minced and digested with 0.5 mg/mL collage-
nase I (Sigma-Aldrich) for 2 h and 5 additional minutes
with 0.05% trypsin (Gibco) at 37ºC in DMEM (Gibco).
Digestion was stopped by adding a final concentration
of 5% human Serum B (hSerB, Banc de Sang i Teixits)
and passed through 100 µm filters (Millipore) in order
to discard undigested tissue fragments (Figure 1, bottom
panel). The flow-through was centrifuged at 300g for
10 min. In both cases, subsequent cell expansion was
performed using 20 mL of expansion medium consisting
of DMEM supplemented with 20% hSerB, 2x104 IU/mL
penicillin, 20 mg/mL streptomycin, and 120 µg/mL
amphotericin B (Invitrogen).
Cell number and viability were determined by the hae-
mocytometer-based Trypan Blue dye exclusion assay,
and the MSC nature of expanded cells was determined
according to the criteria established by the International
Society for Cellular Therapy [4], including the evaluation
of characteristic features such as adherence to plastic and
morphology (assessed by bright field microscopy in Leica
DMIL LED), immunophenotype by flow cytometry in a
FACSCalibur (BD Biosciences). FACS analysis was per-
formed to evaluate expression of surface markers CD31
(555445, BD), CD45 (HI30, BD Biosciences), CD90
(5E10, BD Biosciences), CD73 (AD2, BD Biosciences),
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CD105 (43A4E1 clone, Miltenyi) and HLA-DR (TU36,
BD Biosciences) in a FACS Calibur flow cytometer (BD
Biosciences). PE-conjugated IgG1 (X40, BD Biosciences)
and FITC-conjugated IgG2bk (27-35, BD Biosciences)
antibodies were used as isotype controls. Multipotential-
ity of UC-MSC was assessed in vitro using StemPro
differentiation media (Gibco) and specific stainings for
the detection of cell fate into either osteogenic, chondro-
genic or adipogenic lineages, were performed as
described elsewhere [5].
Results
Starting umbilical cord tissue was cut into two frag-
ments of same size weighting 7.6 ± 1.9 g and 7.2 ± 1.5 g
(n = 10), for testing the mechanical and enzymatic
derivation protocols, respectively. Each method pre-
sented a series of advantages and disadvantages related
to the use of a number of reagents in the case of the
enzymatic method and extensive manipulation in an
open circuit in the case of the mechanical scrapping
method. However, all cases resulted in the successful
derivation of at least 1x106 MSC within 24 days, suita-
ble for cryopreservation and subsequent scale up for use
in preclinical and/or clinical studies.
Phenotypically, UC-MSC derived following the
mechanical method were 99.2% ± 0.7% CD90, 0.6% ±
0.6% CD45, 99.0% ± 0.7%CD73, 0.7% ± 0.8 CD31,
99.1% ± 0.5 CD105, and 0.7% ± 0.8 HLA-DR (n = 3).
Similarly, UC-MSC derived following the enzymatic
method were 99.1% ± 1.2% CD90, 0.7% ± 1.3% CD45,
Figure 1 Derivation of UC-MSC. Initial processing of the source tissue is shown in the top panel, while the mechanical and enzymatic
methods are shown in the middle and bottom panels, respectively. Scale bars= 100 µm (mechanical) & 200 µm (enzymatic).
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97.2% ± 2.5%CD73, 1.5% ± 2.9 CD31, 99.0% ± 1.1
CD105, and 0.7% ± 1.2 HLA-DR (n = 4).
Both methods tested proved to generate cell lines that
retained osteogenic, chondrogenic, and adipogenic
differentiation potential of the cells as assayed in vitro
(Fig. 1). The combination of differentiation assays,
growth profiles, morphology assessment and cytometric
phenotype confirmed the MSC nature of the cells
derived by following the two methodologies described in
this study.
Conclusions
Current methods for MSC derivation from umbilical
cord require very fresh tissue within hours from birth,
are tedious and yields are low. UC-MSC produced fol-
lowing the methods described in this work are simple,
require small quantities of starting material and can be
implemented as initial derivation step in any GMP-
compliant bioprocess aiming at producing off-the-shelf
cryopreserved products for cell therapy.
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